Global Melanoma Therapeutics Market to Reach $9.5 Billion by 2030
The global market for Melanoma Therapeutics estimated at US$3.3 Billion in the year 2022, is projected to reach a revised size of US$9.5 Billion by 2030, growing at a CAGR of 13.9% over the analysis period 2022-2030. Cutaneous Melanoma, one of the segments analyzed in the report, is projected to record a 14% CAGR and reach US$4.3 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Ocular Melanoma segment is readjusted to a revised 14.9% CAGR for the next 8-year period.
The U.S. Market is Estimated at $911.9 Million, While China is Forecast to Grow at 18.8% CAGR
The Melanoma Therapeutics market in the U.S. is estimated at US$911.9 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$2.2 Billion by the year 2030 trailing a CAGR of 18.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 10.3% and 11.8% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 11% CAGR. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.5 Billion by the year 2030.Select Competitors (Total 14 Featured) -
- Amgen, Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Eisai Co., Ltd.
- F. Hoffmann-La Roche AG
- Iovance Biotherapeutics, Inc.
- Merck & Co., Inc.
- Novartis International AG
- Pfizer, Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERSIII. MARKET ANALYSISSOUTH KOREAREST OF ASIA-PACIFICARGENTINABRAZILMEXICOREST OF LATIN AMERICAIRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EASTIV. COMPETITION
1. MARKET OVERVIEW
- Influencer Market Insights
- World Market Trajectories
- Melanoma Therapeutics - Global Key Competitors Percentage Market Share in 2022 (E)
- Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
- Impact of Covid-19 and a Looming Global Recession
- Cancer Evolves Into the Global Epidemic
- Global New Cancer Incidence (In Million) for the Year 2020
- COVID-19 Extends a Major Setback to the World’s Battle Against Cancer
- Melanoma: Disease Causes, Risks, Types, Symptoms, Diagnosis & Survival
- Global Skin Cancer Cases (Per 100,000 People) by Country for the Year 2020
3. MARKET TRENDS & DRIVERS
- Depletion of Ozone Layer & Increase in Ground-Level Ultraviolet Radiation: A Key Reason for Rising Incidence of Melanoma
- Melanoma Mortality in the U.S. for the Years 2015, 2017, 2019, 2022
- New Melanoma Cancer Cases in the U.S. for the Year 2021
- Targeted Therapies Grow in Popularity for Treating Melanoma
- Advancements in the Field of Genomics Brings Hope for the Development of More Potent Cancer Drugs
- What Are the Approved Drugs for Melanoma?
- Artificial Intelligence Helps Speed Up & Automate Melanoma Diagnosis
- Global Market for AI in Healthcare (US$ Billion) for Years 2020, 2022 & 2024
4. GLOBAL MARKET PERSPECTIVE
- Table 1: World Recent Past, Current & Future Analysis for Melanoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 2: World Historic Review for Melanoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 3: World 18-Year Perspective for Melanoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2023 & 2030
- Table 4: World Recent Past, Current & Future Analysis for Cutaneous Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 5: World Historic Review for Cutaneous Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 6: World 18-Year Perspective for Cutaneous Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 7: World Recent Past, Current & Future Analysis for Ocular Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 8: World Historic Review for Ocular Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 9: World 18-Year Perspective for Ocular Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 10: World Recent Past, Current & Future Analysis for Mucosal Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 11: World Historic Review for Mucosal Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 12: World 18-Year Perspective for Mucosal Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 13: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 14: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 15: World 18-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 16: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 17: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 18: World 18-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 19: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 20: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 21: World 18-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 22: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 23: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 24: World 18-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 25: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 26: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 27: World 18-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2023 & 2030
- Table 28: World Melanoma Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2012 through 2030
UNITED STATES
- Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
- Table 29: USA Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 30: USA Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 31: USA 18-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2012, 2023 & 2030
- Table 32: USA Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 33: USA Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 34: USA 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030
CANADA
- Table 35: Canada Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 36: Canada Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 37: Canada 18-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2012, 2023 & 2030
- Table 38: Canada Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 39: Canada Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 40: Canada 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030
JAPAN
- Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
- Table 41: Japan Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 42: Japan Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 43: Japan 18-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2012, 2023 & 2030
- Table 44: Japan Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 45: Japan Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 46: Japan 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030
CHINA
- Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
- Table 47: China Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 48: China Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 49: China 18-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2012, 2023 & 2030
- Table 50: China Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 51: China Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 52: China 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030
EUROPE
- Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
- Table 53: Europe Recent Past, Current & Future Analysis for Melanoma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 54: Europe Historic Review for Melanoma Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 55: Europe 18-Year Perspective for Melanoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2023 & 2030
- Table 56: Europe Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 57: Europe Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 58: Europe 18-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2012, 2023 & 2030
- Table 59: Europe Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 60: Europe Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 61: Europe 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030
FRANCE
- Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
- Table 62: France Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 63: France Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 64: France 18-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2012, 2023 & 2030
- Table 65: France Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 66: France Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 67: France 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030
GERMANY
- Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
- Table 68: Germany Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 69: Germany Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 70: Germany 18-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2012, 2023 & 2030
- Table 71: Germany Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 72: Germany Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 73: Germany 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030
ITALY
- Table 74: Italy Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 75: Italy Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 76: Italy 18-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2012, 2023 & 2030
- Table 77: Italy Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 78: Italy Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 79: Italy 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030
UNITED KINGDOM
- Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
- Table 80: UK Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 81: UK Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 82: UK 18-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2012, 2023 & 2030
- Table 83: UK Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 84: UK Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 85: UK 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030
SPAIN
- Table 86: Spain Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 87: Spain Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 88: Spain 18-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2012, 2023 & 2030
- Table 89: Spain Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 90: Spain Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 91: Spain 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030
RUSSIA
- Table 92: Russia Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 93: Russia Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 94: Russia 18-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2012, 2023 & 2030
- Table 95: Russia Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 96: Russia Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 97: Russia 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030
REST OF EUROPE
- Table 98: Rest of Europe Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 99: Rest of Europe Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 100: Rest of Europe 18-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2012, 2023 & 2030
- Table 101: Rest of Europe Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 102: Rest of Europe Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 103: Rest of Europe 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030
ASIA-PACIFIC
- Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
- Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Melanoma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
- Table 105: Asia-Pacific Historic Review for Melanoma Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 106: Asia-Pacific 18-Year Perspective for Melanoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2023 & 2030
- Table 107: Asia-Pacific Recent Past, Current & Future Analysis for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 108: Asia-Pacific Historic Review for Melanoma Therapeutics by Type - Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 109: Asia-Pacific 18-Year Perspective for Melanoma Therapeutics by Type - Percentage Breakdown of Value Sales for Cutaneous Melanoma, Ocular Melanoma and Mucosal Melanoma for the Years 2012, 2023 & 2030
- Table 110: Asia-Pacific Recent Past, Current & Future Analysis for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
- Table 111: Asia-Pacific Historic Review for Melanoma Therapeutics by Therapy - Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2021 and % CAGR
- Table 112: Asia-Pacific 18-Year Perspective for Melanoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Immunotherapy, Targeted Therapy, Chemotherapy, Radiation Therapy and Surgery for the Years 2012, 2023 & 2030
AUSTRALIA
- Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
INDIA
- Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
LATIN AMERICA
- Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
MIDDLE EAST
- Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
AFRICA
- Melanoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Amgen, Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb Company
- Eisai Co., Ltd.
- F. Hoffmann-La Roche AG
- Iovance Biotherapeutics, Inc.
- Merck & Co., Inc.
- Novartis International AG
- Pfizer, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 162 |
| Published | April 2024 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 3.3 Billion |
| Forecasted Market Value ( USD | $ 9.5 Billion |
| Compound Annual Growth Rate | 14.1% |
| Regions Covered | Global |
